Page last updated: 2024-08-26

cb 10375 and Carcinoma 256, Walker

cb 10375 has been researched along with Carcinoma 256, Walker in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abel, G; Goddard, PM; Harrap, KR; Judson, IR; Newell, DR; Rutty, CJ1

Other Studies

1 other study(ies) available for cb 10375 and Carcinoma 256, Walker

ArticleYear
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
    Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:3

    Topics: Altretamine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Plasmacytoma; Rats; Rats, Inbred Strains; Solubility; Triazines

1986